SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Acuite upgrades credit ratings of Bal Pharma

22 Feb 2022 Evaluate

Credit rating agency -- Acuite has upgraded credit ratings of Bal Pharma. Long Term Fund based facilities has been upgraded to ‘BBB-’ stable from ‘BB+’ positive. Short term Non fund based facilities has been upgraded to ‘A3’ from ‘A4+’. Also, Long term-Term Loan has been upgraded to ‘BBB-’ stable from ‘BB+’ positive.

Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.

Bal Pharma Share Price

78.47 0.00 (0.00%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1242.75
Cipla 1230.00
Zydus Lifesciences 935.00
Lupin 2337.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×